New 340B Drug Rebate Program: What Healthcare Providers Need to No
The 340B program, a vital resource for hospitals and clinics serving vulnerable patients, is undergoing a important change. A new rebate model is rolling out, designed to increase transparency and accountability in drug pricing. This article breaks down what you need to know as a healthcare provider, covering the program’s mechanics, potential challenges, and what it means for your association.
Understanding the 340B Program & The New Rebate Model
For decades, the 340B program has allowed eligible healthcare organizations – primarily those serving low-income and underserved communities – to purchase outpatient drugs at considerably reduced prices. This allows you to stretch your resources further and provide affordable care. However, concerns about program integrity and ensuring manufacturers adhere to the spirit of the law have led to this new pilot program.
The core of the change centers around a new verification process managed by an IT platform called Beacon. Hear’s how it works:
* Data Submission: You’ll now need to back up each dispensed drug’s eligibility for 340B savings by submitting key data to Beacon. This includes the claim number, prescriber’s ID, and your 340B provider ID.
* Eligibility Verification: Beacon will verify that the drug was dispensed at a 340B-eligible location and the claim was submitted within the required timeframe.
* Rebate Issuance: Once approved,drug manufacturers are obligated to pay rebates within 10 days,covering the difference between the wholesaler price and the 340B price.
* Accountability: HRSA (Health Resources & Services governance) will closely monitor rebate payments. frequent delays could result in a manufacturer losing their participation in the program.
Which Drugs Are Affected?
The initial pilot program focuses on a select list of high-revenue drugs. These were also chosen for Medicare price negotiation, highlighting their significant impact on healthcare costs. Here’s a look at the drugs currently included:
* Stelara (Johnson & Johnson): A plaque psoriasis treatment, generating $10.4 billion in sales last year.
* Eliquis (Bristol myers Squibb): A blood thinner, with $9.6 billion in U.S. sales in 2024.
* Novolog & Fiasp (novo Nordisk): Fast-acting insulins, commonly prescribed for diabetes management.
You can view a detailed table of the included drugs here.
What Challenges Can you Expect?
While the goal of the new model is improved transparency, many hospitals and clinics are raising concerns.
* Administrative Burden: Tracking and submitting the required data will undoubtedly increase administrative workload and costs. Many facilities worry they lack the resources to manage this effectively.
* Potential for denials: Providers fear manufacturers may seek reasons to deny legitimate rebates,avoiding discounts.
* Increased Bureaucracy: As Jennifer DeCubellis, CEO of America’s Essential Hospitals, stated, “Hospitals now have to manage a whole new set of administrative burdens, requiring more bureaucracy and more paperwork, with no benefit to patients’ ability to access discounted drugs.”
These concerns are valid. It’s crucial to proactively assess your organization’s capacity to handle the new requirements and advocate for streamlined processes.
why Are Drug Manufacturers Pushing Back?
Drug manufacturers aren’t embracing these changes. They’ve actively lobbied against the program and even filed lawsuits to curtail it. Their primary concern? Revenue.
The drugs selected for the rebate program represent a substantial portion of their earnings. For example, Stelara accounts for nearly 12% of Johnson & Johnson’s total revenue. Reducing 340B discounts could further boost their revenue, especially as Medicare price negotiations take effect.
What’s next?
HRSA has indicated it may expand the 340B rebate pilot to include additional drugs not currently subject to Medicare price negotiation. This means the scope of the program could broaden significantly in the future.
Preparing Your Organization
Here are some steps you can take now to prepare:
* Familiarize yourself with Beacon: